Etelcalcetide HCl is the HCl salt of etelcalcetide is a calcium-sensing receptor agonist for the treatment of secondary hyperparathyroidism for patients with chronic kidney disease (CKD) on hemodialysis.

NPS-2143 HCl is a potent and selective calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroid hormone secretion, respectively.

Tecalcet Hydrochloride, an orally active calcimimetic compound, allosterically and positively modulates the calcium-sensing receptor (CaSR). Tecalcet Hydrochloride increases the sensitivity to activation by extracellular Ca2+.

Cinacalcet is an orally active, second-generation calcimimetic compound and represents a class of compounds for the treatment of hyperparathyroidism.

Cinacalcet HCl is an orally active calcimimetic compound and represents a class of compounds for the treatment of hyperparathyroidism.

Stretch-activated calcium channel blocker; calcium-sensing receptor agonist

Ligustroflavone, extracted from Ligustrum lucidum, is a potential candidate as calcium-sensing receptor (CaSR) antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice[1].

Strontium ranelate stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation.